Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD

American Journal of Kidney Diseases

Volumn 43, Issue 6, 2004, Pages 1056-1064

  Suzuki, Hiromichi ^a   Kanno, Yoshihiko ^a   Sugahara, Soichi ^a   Okada, Hirokazu ^a   Nakamoto, Hidetomo ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antihypertensive agents; Weekly creatinine clearance (CrCI)

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DOXAZOSIN; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; JAPAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MALE; MORBIDITY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SURVIVAL; TREATMENT OUTCOME; URINE VOLUME;

EID: 2542497016     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.01.019     Document Type: Article

References (30)

1. Nolph KD: Comparison of continuous ambulatory peritoneal dialysis and hemodialysis. Kidney Int Suppl 24: S123-S131, 1988
2. Fenton SS, Schaubel DE, Desmeules M, et al: Hemodialysis versus peritoneal dialysis: A comparison of adjusted mortality rates. Am J Kidney Dis 30:334-342, 1997
3. Gokal R, Figueras M, Olle A, Rovira J, Badia X: Outcomes in peritoneal dialysis and hemodialysis-A comparative assessment of survival and quality of life. Nephrol Dial Transplant 14:S24-S30, 1999 (suppl 6)
4. Suzuki T, Kanno Y, Nakamoto N, Okada H, Sugahara S, Suzuki H: Peritoneal dialysis versus hemodialysis: A five-year comparison of survival and effects on the cardiovascular system, erythropoiesis, and calcium metabolism. Adv Perit Dial 19:148-154, 2003
5. Van Biesen W, Vanholder R, Lameire N: The role of peritoneal dialysis as the first-line renal replacement modality. Perit Dial Int 20:375-383, 2000
6. Bargman JM, Thorpe KE, Churchill DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12:2158-2162, 2001
7. Moist LM, Port FK, Orzol SM, et al: Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 11:556-564, 2000
8. Rahman M, Smith MC: Hypertension in hemodialysis patients. Curr Hypertens Rep 3:496-502, 2001
9. Horl MP, Horl WH: Hypertension and dialysis. Kidney Blood Press Res 26:76-81, 2003
10. Cheigh JS, Kim H: Hypertension in continuous ambulatory peritoneal dialysis patients: What do we know and what can we do about it? Perit Dial Int 19:S138-S143, 1999 (suppl 2)
11. Gunal AI, Duman S, Ozkahya M, et al: Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 37:588-593, 2001
12. Shoda J, Nakamoto H, Okada H, Suzuki H: Impact of introduction of continuous ambulatory peritoneal dialysis on blood pressure: Analysis of 24-hour ambulatory blood pressure. Adv Perit Dial 16:97-101, 2000
13. Plum J, Bunten B, Nemeth R, Grabensee B: Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 9:2223-2234, 1998
14. Hilgers KF, Mann JFE: ACE inhibitors versus AT1 receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 13:1100-1108, 2002
15. Burt VL, Cutler JA, Higgins M, et al: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 26:60-69, 1995
16. Bakris GL, Siomos M, Richardson D, et al: ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. VAL-K Study Group. Kidney Int 58:2084-2092, 2000
17. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC: Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 139:105-112, 2003
18. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30:659-664, 1997
19. Taal M, Brenner B: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 57:1803-1817, 2000
20. Lewis E, Hunsicker L, Clarke W, et al, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
21. Remuzzi G, Ruggenenti P, Perico N: Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 136:604-615, 2002
22. Hollenberg NK, Osei SY, Lansang MC, Price DA, Fisher ND: Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man. J Renin Angiotensin Aldosterone Syst 2:14-18, 2001
23. Meloni C, Morosetti M, Suraci C, et al: Severe dietary protein restriction in overt diabetic nephropathy: Benefits or risks? J Ren Nutr 12:96-101, 2002
24. Gokal R: Peritoneal dialysis in the 21st century: An analysis of current problems and future developments. J Am Soc Nephrol 13:S104-S116, 2002 (suppl 1)
25. National Kidney Foundation: DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy. Am J Kidney Dis 30:S67-S136, 1997 (suppl 2)
26. Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 12:1046-1051, 2001
27. Honda K, Nitta K, Horita S, Yumura W, Nihei H: Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 72: 171-176, 1996
28. Lavoie JL, Sigmund CD: Minireview: Overview of the renin-angiotensin system-An endocrine and paracrine system. Endocrinology 144:2179-2183, 2003
29. Duman S, Gunal AI, Sen S, et al: Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 21:219-224, 2001
30. Remuzzi A, Perico N, Sangalli F, et al: ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 276:F457-F466, 1999